A recent report utilized MCC950 as a specific NLRP3 inhibitor in vivo in CF animal models, which resulted in significantly reduced airway inflammation and improved Pseudomonas clearance (McElvaney et al., 2019). This evidence concerns the gene NLRP3 and cystic fibrosis.